MedTrace Logo

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

NCT06034275 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-11-15

No results posted yet for this study

Summary

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

Conditions

Interventions

DRUG

VIP943 (QW)

VIP943 will be administered by IV Infusion weekly

DRUG

VIP943 (BIW)

VIP943 will be administered by IV Infusion bi-weekly

Sponsors & Collaborators

  • Vincerx Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Vincerx Study Director · Vincerx Pharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-13
Primary Completion
2025-05-30
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06034275 on ClinicalTrials.gov